286 related articles for article (PubMed ID: 18295747)
1. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery.
Samaha AN; Reckless GE; Seeman P; Diwan M; Nobrega JN; Kapur S
Biol Psychiatry; 2008 Jul; 64(2):145-52. PubMed ID: 18295747
[TBL] [Abstract][Full Text] [Related]
2. Effects of the adenosine A 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide.
Betz AJ; Vontell R; Valenta J; Worden L; Sink KS; Font L; Correa M; Sager TN; Salamone JD
Neuroscience; 2009 Sep; 163(1):97-108. PubMed ID: 19467297
[TBL] [Abstract][Full Text] [Related]
3. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
4. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions.
Merchant KM; Dobie DJ; Filloux FM; Totzke M; Aravagiri M; Dorsa DM
J Pharmacol Exp Ther; 1994 Oct; 271(1):460-71. PubMed ID: 7965747
[TBL] [Abstract][Full Text] [Related]
5. Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity.
Obuchowicz E; Krysiak R; Wieronska JM; Smialowska M; Herman ZS
Neuropeptides; 2005 Oct; 39(5):515-23. PubMed ID: 16154634
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy.
Kapur S; VanderSpek SC; Brownlee BA; Nobrega JN
J Pharmacol Exp Ther; 2003 May; 305(2):625-31. PubMed ID: 12606608
[TBL] [Abstract][Full Text] [Related]
7. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
[TBL] [Abstract][Full Text] [Related]
8. Developmental striatal critical period of activity-dependent plasticity is also a window of susceptibility for haloperidol induced adult motor alterations.
Soiza-Reilly M; Azcurra JM
Neurotoxicol Teratol; 2009; 31(4):191-7. PubMed ID: 19336253
[TBL] [Abstract][Full Text] [Related]
9. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
11. [Induction by neuroleptics of certain genes in the central nervous system].
Rogue P; Vincendon G
Ann Med Psychol (Paris); 1992; 150(2-3):124-6. PubMed ID: 1343505
[TBL] [Abstract][Full Text] [Related]
12. The effects of apomorphine and D-amphetamine on striatal c-Fos expression in Sprague-Dawley and Long Evans rats and their F1 progeny.
Saint Marie RL; Neary AC; Shoemaker JM; Swerdlow NR
Brain Res; 2006 Nov; 1119(1):203-14. PubMed ID: 16979142
[TBL] [Abstract][Full Text] [Related]
13. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
[TBL] [Abstract][Full Text] [Related]
14. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
15. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic haloperidol treatment on stimulated synaptic overflow of dopamine in the rat striatum.
Wiedemann DJ; Garris PA; Near JA; Wightman RM
J Pharmacol Exp Ther; 1992 May; 261(2):574-9. PubMed ID: 1533666
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
Schröder U; Schröder H; Augustin W; Sabel BA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
[TBL] [Abstract][Full Text] [Related]
18. PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties.
Tang AH; Franklin SR; Himes CS; Smith MW; Tenbrink RE
J Pharmacol Exp Ther; 1997 Apr; 281(1):440-7. PubMed ID: 9103528
[TBL] [Abstract][Full Text] [Related]
19. Opposite effects of low versus high dose haloperidol treatments on spontaneous and apomorphine induced motor behavior: evidence that at a very low dose haloperidol acts as an indirect dopamine agonist.
Dias FR; de Matos LW; Sampaio Mde F; Carey RJ; Carrera MP
Behav Brain Res; 2012 Apr; 229(1):153-9. PubMed ID: 22244923
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of dopamine and AMPA receptor antagonists on the expression of conditioned avoidance responding in rats.
Boivin GA; Beninger RJ
Behav Neurosci; 2008 Apr; 122(2):377-84. PubMed ID: 18410176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
